November 2022
-
11.03.2022 Covid-19 Research Vaccines Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19
October 2022
-
10.28.2022 Medicines Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union -
10.20.2022 Vaccines Advisory Committee on Immunization Practices Recommends Pfizer’s PREVNAR 20® for Adults Previously Vaccinated with PREVNAR 13® -
10.19.2022 Covid-19 Vaccines Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union -
10.17.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review RSV Data Presented at ID Week 2022
September 2022
-
09.28.2022 Covid-19 Vaccines Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age -
09.24.2022 Leadership Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19 -
09.22.2022 Medicines Research Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A Has Re-Opened Recruitment -
09.16.2022 Vaccines Pfizer and BioNTech Receive Positive CHMP Opinion for Conversion of COMIRNATY® Conditional Marketing Authorization to Full Marketing Authorization in the European Union
August 2022
-
08.22.2022 Medicines Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion (containing benzyl alcohol), Due To The Potential Presence of Visible Particulates -
08.15.2022 Covid-19 Statement from Pfizer Chairman and CEO Albert Bourla on Testing Positive for COVID-19 -
08.11.2022 Finance Pfizer Statement on Zantac Litigation